Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID-PsA: Certolizumab Pegol in Psoriatic Arthritis
NCT01087788Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2010
- Primary completion
- Nov 2011
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 15
01
Overview
A Phase 3 trial of certolizumab pegol in psoriatic arthritis (PsA), sponsored by UCB. Started Mar 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01087788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01087788.